Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
Cancers, 2021 Activating mutations in KRAS are present in 25% of human cancers. When mutated, the KRAS protein becomes constitutively active, stimulating various effector pathways and leading to the deregulation of key cellular processes, including the suppression of apoptosis and enhancement of proliferation.
Yuta Adachi +3 more
openaire +4 more sources
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy [PDF]
Molecular Cancer, 2019 Lung cancer patients with KRAS mutation(s) have a poor prognosis due in part to the development of resistance to currently available therapeutic interventions. Development of a new class of anticancer agents that directly targets KRAS may provide a more attractive option for the treatment of KRAS-mutant lung cancer.Here we identified a small molecule ...
Ke Xu +8 more
openaire +4 more sources
Structure, 2017 Mutations in members of the RAS family of small GTPases have been associated with numerous human cancers. However, RAS family members are notoriously difficult to target. In this issue of Structure, Lu et al. (2017) examine the effects of two compounds with distinct chemical scaffolds on the structure and dynamics of an oncogenic KRAS mutant, thus ...
Daniel J, Deredge, Patrick L, Wintrode
openaire +2 more sources
Cold Spring Harbor Perspectives in Medicine, 2018 Oncogenic Kras are genetic dependencies for the majority of pancreatic and colorectal adenocarcinomas; however, much remains to be understood regarding its tropism to these carcinomas. Recently developed organoid technology presents a more representative model culture system for pancreatic and colon epithelial tissues as well as better fostering the ...
Derek, Cheng, David, Tuveson
openaire +2 more sources
Mutant KRAS-m<sup>6</sup>A Epitranscriptome Axis Promotes Colorectal Cancer and is a Therapeutic Target. [PDF]
Adv Sci (Weinh)Mutant KRAS‐m6A axis promotes colorectal cancer (CRC) progression. Mutant KRAS stabilizes METTL3, leading to increased m6A‐modified BCL9L mRNA and translation of BCL9L protein. BCL9L in turn mediates TGF‐β secretion to induce differentiation of Treg and an immunosuppressive microenvironment.
Chen D +12 more
europepmc +2 more sources
Flywheel proof mass actuator for active vibration control [PDF]
, 2023 This paper presents the experimental results of a new proof mass actuator for the implementation of velocity feedback control loops to reduce the flexural vibration of a thin plate structure.
Kras A., Gardonio P.
core +1 more source
Selenium Nanoparticles Selectively Target KRAS G13D to Inhibit Colorectal Cancer. [PDF]
Adv Sci (Weinh)The mechanisms of SeNPs therapy in cancer treatment, encompass three parallel actions: (1) seleno‐amino acids, key metabolites, upregulate GPX2 expression, thereby inhibiting tumor metastasis via the GPX2‐HIF1α‐VEGF signaling pathway; (2) selenite (SeO32−), an inorganic metabolite, forms hydrogen bonds with amino acid residues 13–17 of the KRAS G13D ...
Liu X +13 more
europepmc +2 more sources
KRAS mutation analysis by PCR : a comparison of two methods [PDF]
, 2015 Background: KRAS mutation assays are important companion diagnostic tests to guide anti-EGFR antibody treatment of metastatic colorectal cancer. Direct comparison of newer diagnostic methods with existing methods is an important part of validation of ...
Lucas, Katie +9 more
core +2 more sources
Impact of the Specific Mutation in KRAS Codon 12 Mutated Tumors on Treatment Efficacy in Patients with Metastatic Colorectal Cancer Receiving Cetuximab-Based First-Line Therapy: A Pooled Analysis of Three Trials [PDF]
, 2012 Purpose: This study investigated the impact of specific mutations in codon 12 of the Kirsten-ras (KRAS) gene on treatment efficacy in patients with metastatic colorectal cancer (mCRC).
Zielinski, Christoph C. +12 more
core +1 more source
Deep sequence analysis of non-small cell lung cancer: Integrated analysis of gene expression, alternative splicing, and single nucleotide variations in lung adenocarcinomas with and without oncogenic KRAS mutations [PDF]
, 2012 KRAS mutations are highly prevalent in non-small cell lung cancer (NSCLC), and tumors harboring these mutations tend to be aggressive and resistant to chemotherapy.
David Rossell +65 more
core +1 more source